PhaseBio Pharmaceuticals Inc

NASDAQ:PHAS   3:59:51 PM EDT
3.05
+0.04 (+1.33%)
Earnings Announcements

PhaseBio Reports Q2 Loss Per Share Of $0.60

Published: 08/12/2021 12:56 GMT
PhaseBio Pharmaceuticals Inc (PHAS) - Phasebio Reports Second-quarter 2021 Financial Results and Recent Business Highlights.
Phasebio Pharmaceuticals - Sublicense Revenue for Quarter Was $10.3 Million.
Phasebio Pharmaceuticals Inc Qtrly Loss per Share $0.60.
Revenue is expected to be $0.25 Million
Adjusted EPS is expected to be -$0.60

Next Quarter Revenue Guidance is expected to be $0.15 Million
Next Quarter EPS Guidance is expected to be -$0.55

More details on our Analysts Page.